HORSHAM, PA — Clinical ink announced a strategic alliance with The Boston Clinical Research Institute (BCRI), an Academic Research Organization (ARO) based in Boston, Massachusetts. The alliance will combine BCRI’s leadership in clinical strategy, therapeutic area expertise, and academic collaboration with Clinical ink’s expertise in eSource technology, including Direct Data Capture (DDC), electronic Clinical Outcomes Assessments (eCOA), and digital biomarkers.
BCRI provides scientific consultancy in study design, patient-centric modalities, endpoint selection, and complex data analysis by leveraging expert clinicians and key opinion leaders from premier medical institutions—with a goal to help advance health and quality of life around the world. To date, the institute has managed 450 studies which have enrolled over 160,000 patients, and has played a role in more than 50 FDA submissions.
“We are extremely pleased to announce this alliance,” said Michael Gibson, MD, President and Chief Executive Officer of BCRI. “The path forward for global clinical trials will be forged via the expert design and planning of therapeutic thought leaders who will recommend the implementation of innovative and clinically-relevant eSource technology.”
Commenting on the alliance, Dr. Jonathan Goldman, MD, the Chief Executive Officer of Clinical ink, said, “We are delighted that Dr. Gibson and BCRI have aligned with Clinical ink. This relationship provides our trusted Sponsor and CRO partners access to a breadth of clinical and key opinion leader expertise in trial design, as well as clinical and digital endpoint selection across a full range of therapeutic areas.”
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.